About AmyPore

About company

AmyPore develops an innovative drug that targets a common mechanism of Alzheimer's and Parkinson's diseases. Their lead product AmyP53 is a chimeric peptide (Alzheimer's / Parkinson's) generated through an innovative strategy of artificial intelligence applied to the molecular neuroscience. AmyP53 is capable of blocking the formation of neurotoxic structures (oligomers of amyloid proteins) responsible for these two neurodegenerative diseases (new therapeutic target, the only molecule in the world capable of acting on Alzheimer's and Parkinson's). Their drug candidate is thus the first representative of a new therapeutic class that inhibits a fundamental mechanism common to Alzheimer's and Parkinson's diseases.